Results 221 to 230 of about 74,008 (304)
ABSTRACT Background: Therapeutic advances have profoundly improved outcomes in multiple myeloma (MM) in high‐income countries. In sub‐Saharan Africa; however, data remain scarce and access to novel therapies is limited. We aimed to characterize the clinical presentation, treatment strategies, and outcomes of MM patients managed in a resource‐limited ...
Nata Dieng +7 more
wiley +1 more source
Beyond binary: graded frailty assessment and outcomes after CAR-T cell therapy in relapsed/refractory multiple myeloma. [PDF]
Hashmi H +14 more
europepmc +1 more source
Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms. [PDF]
Khanlari M +11 more
europepmc +1 more source
ABSTRACT Background Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...
John M. Burke +10 more
wiley +1 more source
ABSTRACT This work describes, to our knowledge, the first reported case of a patient with an MDS/MPN overlap syndrome harboring a novel KRAS::ETNK1 fusion transcript. The disease initially presented with eosinophilia, megakaryocyte expansion, mast cell infiltration, and a background of typical MDS/MPN‐associated mutations (ASXL1, TET2, EZH2, BCOR, and ...
Marianne Caledec +17 more
wiley +1 more source
Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium. [PDF]
Dumas PY +22 more
europepmc +1 more source
First karyotype description of the Indochinese shrew <i>Crocidura indochinensis</i> Robinson et Kloss, 1922 (Mammalia, Eulipotyphla, Soricidae) from Yunnan, China. [PDF]
Jin J, Dai J, Ye J.
europepmc +1 more source
ABSTRACT Introduction Gemtuzumab ozogamicin (GO), a CD33‐targeted antibody–drug conjugate, is approved in combination with daunorubicin/cytarabine for patients ≥ 15 years with de novo, CD33‐positive acute myeloid leukemia (AML). Methods This retrospective, observational study assessed real‐world use, clinical outcomes, and safety of GO in 113 patients ...
Juliette Lambert +8 more
wiley +1 more source

